Recent advances in optical cancer imaging of EGF receptors

Current Medicinal Chemistry

Volumn 19, Issue 28, 2012, Pages 4759-4766

  Kramer Marek, G ^a   Longmire, M R ^a   Choyke, P L ^a   Kobayashi, H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Activatable imaging probe; Affibody; Cancer; Epidermal growth factor receptor; Fluorescence; HER2; Molecular imaging; Monoclonal antibody; Multiple color imaging; Near infrared; Optical imaging; Positron emission tomography; Radionuclide imaging

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; PANITUMUMAB; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIMERIZATION; DRUG EFFICACY; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; FLUORESCENT DYES; HUMANS; NEOPLASMS; OPTICAL IMAGING; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84870469277     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803341584     Document Type: Article

References (65)

1. Ciardiello, F.; Tortora, G., EGFR antagonists in cancer treatment. N Engl J Med, 2008, 358, 1160-1174.
2. Jones, H.E.; Gee, J.M.; Taylor, K.M.; Barrow, D.; Williams, H.D.; Rubini, M.; Nicholson, R.I., Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer, 2005, 12 Suppl 1, S173-182.
3. Lurje, G.; Lenz, H.J., EGFR signaling and drug discovery. Oncology, 2009, 77, 400-410.
4. Fass, L., Imaging and cancer: a review. Mol Oncol, 2008, 2, 115-152.
5. Cai, W.; Niu, G.; Chen, X., Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging, 2008, 35, 186-208.
6. Citri, A.; Yarden, Y., EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 2006, 7, 505-516.
7. Yarden, Y.; Sliwkowski, M.X., Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001, 2, 127-137.
8. Wujcik, D., EGFR as a target: rationale for therapy. Semin Oncol Nurs, 2006, 22, 5-9.
9. Herbst, R.S., Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 2004, 59, 21-26.
10. Hatanpaa, K.J.; Burma, S.; Zhao, D.W.; Habib, A.A., Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance. Neoplasia, 2010, 12, 675-684.
11. Levitzki, A., EGF receptor as a therapeutic target. Lung Cancer, 2003, 41 Suppl 1, S9-14.
12. Chan, S.K.; Hill, M.E.; Gullick, W.J., The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia, 2006, 11, 3-11.
13. Capala, J.; Bouchelouche, K., Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol, 2010, 22, 559-566.
14. Bange, J.; Zwick, E.; Ullrich, A., Molecular targets for breast cancer therapy and prevention. Nat Med, 2001, 7, 548-552.
15. Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li, P.; Monia, B.P.; Nguyen, N.T.; Hortobagyi, G.N.; Hung, M.C.; Yu, D., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127.
16. Vogel, C.L.; Cobleigh, M.A.; Tripathy, D.; Gutheil, J.C.; Harris, L.N.; Fehrenbacher, L.; Slamon, D.J.; Murphy, M.; Novotny, W.F.; Burchmore, M.; Shak, S.; Stewart, S.J.; Press, M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002, 20, 719-726.
17. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A.; Swain, S.M.; Pisansky, T.M.; Fehrenbacher, L.; Kutteh, L.A.; Vogel, V.G.; Visscher, D.W.; Yothers, G.; Jenkins, R.B.; Brown, A.M.; Dakhil, S.R.; Mamounas, E.P.; Lingle, W.L.; Klein, P.M.; Ingle, J.N.; Wolmark, N., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353, 1673-1684.
18. Lower, E.E.; Glass, E.; Blau, R.; Harman, S., HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat, 2009, 113, 301-306.
19. Silverman, J.; Liu, Q.; Bakker, A.; To, W.; Duguay, A.; Alba, B.M.; Smith, R.; Rivas, A.; Li, P.; Le, H.; Whitehorn, E.; Moore, K.W.; Swimmer, C.; Perlroth, V.; Vogt, M.; Kolkman, J.; Stemmer, W.P., Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol, 2005, 23, 1556-1561.
20. Hicke, B.J.; Stephens, A.W.; Gould, T.; Chang, Y.F.; Lynott, C.K.; Heil, J.; Borkowski, S.; Hilger, C.S.; Cook, G.; Warren, S.; Schmidt, P.G., Tumor targeting by an aptamer. J Nucl Med, 2006, 47, 668-678.
21. Nord, K.; Gunneriusson, E.; Ringdahl, J.; Stahl, S.; Uhlen, M.; Nygren, P.A., Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol, 1997, 15, 772-777.
22. Nilsson, F.Y.; Tolmachev, V., Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel, 2007, 10, 167-175.
23. Tolmachev, V.; Orlova, A.; Nilsson, F.Y.; Feldwisch, J.; Wennborg, A.; Abrahmsen, L., Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther, 2007, 7, 555-568.
24. Ahlgren, S.; Tolmachev, V., Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol, 2010, 11, 581-589.
25. Cai, W.; Chen, K.; He, L.; Cao, Q.; Koong, A.; Chen, X., Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging, 2007, 34, 850-858.
26. Carlsson, J.; Gedda, L.; Gronvik, C.; Hartman, T.; Lindstrom, A.; Lindstrom, P.; Lundqvist, H.; Lovqvist, A.; Malmqvist, J.; Olsson, P.; et al., Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int J Radiat Oncol Biol Phys, 1994, 30, 105-115.
27. Reilly, R.M.; Kiarash, R.; Sandhu, J.; Lee, Y.W.; Cameron, R.G.; Hendler, A.; Vallis, K.; Gariepy, J., A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med, 2000, 41, 903-911.
28. Velikyan, I.; Sundberg, A.L.; Lindhe, O.; Hoglund, A.U.; Eriksson, O.; Werner, E.; Carlsson, J.; Bergstrom, M.; Langstrom, B.; Tolmachev, V., Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med, 2005, 46, 1881-1888.
29. Nordberg, E.; Orlova, A.; Friedman, M.; Tolmachev, V.; Stahl, S.; Nilsson, F.Y.; Glimelius, B.; Carlsson, J., In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep, 2008, 19, 853-857.
30. Miao, Z.; Ren, G.; Liu, H.; Jiang, L.; Cheng, Z., Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem, 2010, 21, 947-954.
31. Su, H.; Seimbille, Y.; Ferl, G.Z.; Bodenstein, C.; Fueger, B.; Kim, K.J.; Hsu, Y.T.; Dubinett, S.M.; Phelps, M.E.; Czernin, J.; Weber, W.A., Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging, 2008, 35, 1089-1099.
32. Dijkers, E.C.; Kosterink, J.G.; Rademaker, A.P.; Perk, L.R.; van Dongen, G.A.; Bart, J.; de Jong, J.R.; de Vries, E.G.; Lub-de Hooge, M.N., Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med, 2009, 50, 974-981.
33. Dijkers, E.C.; Oude Munnink, T.H.; Kosterink, J.G.; Brouwers, A.H.; Jager, P.L.; de Jong, J.R.; van Dongen, G.A.; Schroder, C.P.; Lub-de Hooge, M.N.; de Vries, E.G., Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther, 2010, 87, 586-592.
34. Smith-Jones, P.M.; Solit, D.B.; Akhurst, T.; Afroze, F.; Rosen, N.; Larson, S.M., Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol, 2004, 22, 701-706.
35. Reddy, S.; Shaller, C.C.; Doss, M.; Shchaveleva, I.; Marks, J.D.; Yu, J.Q.; Robinson, M.K., Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res, 2011, 17, 1509-1520.
36. Baum, R.P.; Prasad, V.; Muller, D.; Schuchardt, C.; Orlova, A.; Wennborg, A.; Tolmachev, V.; Feldwisch, J., Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Galabeled affibody molecules. J Nucl Med, 2010, 51, 892-897.
37. Longmire M, K.N., Ogawa M, Choyke PL, Kobayashi H., Establishment of multiple color in vivo molecular fluorescence imaging guided real-time surgery for the removal HER2 specific micrometastasis. Cancer Science, 2009, 100(6), 1099-1104.
38. Kosaka, N.; Ogawa, M.; Longmire, M.R.; Choyke, P.L.; Kobayashi, H., Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. J Biomed Opt, 2009, 14.
39. Mitsunaga M, O.M., Kosaka N, Rosenburm LT, Choyke PL, Kobayashi H., Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules. Nature Medicine; in press, 2011.
40. Yu, W.W.; Guo, Y.M.; Zhu, M.; Cai, X.W.; Zhu, Z.F.; Zhao, W.X.; Fu, X.L., Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepatogastroenterology, 2011, 58, 426-431.
41. Koyama, Y.; Hama, Y.; Urano, Y.; Nguyen, D.M.; Choyke, P.L.; Kobayashi, H., Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res, 2007, 13, 2936-2945.
42. Koyama, Y.; Barrett, T.; Hama, Y.; Ravizzini, G.; Choyke, P.L.; Kobayashi, H., In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia, 2007, 9, 1021-1029.
43. Ogawa, M.; Kosaka, N.; Choyke, P.L.; Kobayashi, H., In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res, 2009, 69, 1268-1272.
44. Folli, S.; Westermann, P.; Braichotte, D.; Pelegrin, A.; Wagnieres, G.; van den Bergh, H.; Mach, J.P., Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res, 1994, 54, 2643-2649.
45. Ballou, B.; Fisher, G.W.; Waggoner, A.S.; Farkas, D.L.; Reiland, J.M.; Jaffe, R.; Mujumdar, R.B.; Mujumdar, S.R.; Hakala, T.R., Tumor Labeling in-Vivo Using Cyanine-Conjugated Monoclonal-Antibodies. Cancer Immunol Immun, 1995, 41, 257-263.
46. Miao, Z.; Ren, G.; Liu, H.; Jiang, L.; Cheng, Z., Cy5.5-labeled Affibody molecule for near-infrared fluorescent optical imaging of epidermal growth factor receptor positive tumors. J Biomed Opt, 2010, 15, 036007.
47. Gong, H.; Kovar, J.; Little, G.; Chen, H.; Olive, D.M., In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia, 2010, 12, 139-149.
48. Chernomordik, V.; Hassan, M.; Lee, S.B.; Zielinski, R.; Gandjbakhche, A.; Capala, J., Quantitative analysis of Her2 receptor expression in vivo by nearinfrared optical imaging. Mol Imaging, 2010, 9, 192-200.
49. Sampath, L.; Kwon, S.; Ke, S.; Wang, W.; Schiff, R.; Mawad, M.E.; Sevick-Muraca, E.M., Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med, 2007, 48, 1501-1510.
50. Ogawa, M.; Kosaka, N.; Choyke, P.L.; Kobayashi, H., Tumor-specific detection of an optically targeted antibody combined with a quencherconjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer. Bioconjug Chem, 2009, 20, 147-154.
51. Barrett, T.; Koyama, Y.; Hama, Y.; Ravizzini, G.; Shin, I.S.; Jang, B.S.; Paik, C.H.; Urano, Y.; Choyke, P.L.; Kobayashi, H., In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res, 2007, 13, 6639-6648.
52. Kobayashi, H.; Choyke, P.L., Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res, 2011, 44, 83-90.
53. Ogawa, M.; Kosaka, N.; Choyke, P.L.; Kobayashi, H., H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol, 2009, 4, 535-546.
54. Hama, Y.; Urano, Y.; Koyama, Y.; Choyke, P.L.; Kobayashi, H., Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res, 2007, 67, 3809-3817.
55. Urano, Y.; Asanuma, D.; Hama, Y.; Koyama, Y.; Barrett, T.; Kamiya, M.; Nagano, T.; Watanabe, T.; Hasegawa, A.; Choyke, P.L.; Kobayashi, H., Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med, 2009, 15, 104-109.
56. Ogawa, M.; Kosaka, N.; Regino, C.A.; Mitsunaga, M.; Choyke, P.L.; Kobayashi, H., High sensitivity detection of cancer in vivo using a dualcontrolled activation fluorescent imaging probe based on H-dimer formation and pH activation. Mol Biosyst, 2010, 6, 888-893.
57. Ogawa, M.; Regino, C.A.; Choyke, P.L.; Kobayashi, H., In vivo targetspecific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther, 2009, 8, 232-239.
58. Kosaka, N.; Ogawa, M.; Paik, D.S.; Paik, C.H.; Choyke, P.L.; Kobayashi, H., Semiquantitative assessment of the microdistribution of fluorescencelabeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci, 2010, 101, 820-825.
59. Ogawa, M.; Regino, C.A.; Seidel, J.; Green, M.V.; Xi, W.; Williams, M.; Kosaka, N.; Choyke, P.L.; Kobayashi, H., Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem, 2009, 20, 2177-2184.
60. Gee, M.S.; Upadhyay, R.; Bergquist, H.; Alencar, H.; Reynolds, F.; Maricevich, M.; Weissleder, R.; Josephson, L.; Mahmood, U., Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology, 2008, 248, 925-935.
61. Gleysteen, J.P.; Newman, J.R.; Chhieng, D.; Frost, A.; Zinn, K.R.; Rosenthal, E.L., Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck, 2008, 30, 782-789.
62. Kosaka, N.; Ogawa, M.; Longmire, M.R.; Choyke, P.L.; Kobayashi, H., Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. J Biomed Opt, 2009, 14, 014023.
63. Ogawa, M.; Kosaka, N.; Longmire, M.R.; Urano, Y.; Choyke, P.L.; Kobayashi, H., Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm, 2009, 6, 386-395.
64. Schulke, N.; Varlamova, O.A.; Donovan, G.P.; Ma, D.; Gardner, J.P.; Morrissey, D.M.; Arrigale, R.R.; Zhan, C.; Chodera, A.J.; Surowitz, K.G.; Maddon, P.J.; Heston, W.D.; Olson, W.C., The homodimer of prostatespecific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A, 2003, 100, 12590-12595.
65. Nakajima, T.; Mitsunaga, M.; Bander, N.H.; Heston, W.D.; Choyke, P.L.; Kobayashi, H., Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibody-Indocyanine Green (ICG) Conjugate. Bioconjug Chem, 2011.